SCHEMBL6189802

SCHEMBL6189802

CCOc1ccccc1NC(=O)OCCN1CCN(c2cccc(NC(=O)C3=CCCN(C)C3)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.45
ADRA1A P35348 1/20 0.45
DRD3 P35462 1/20 0.45
VCP P55072 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 5/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
BLM P54132 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654673 0.85 MAPT (0.56) DRD2ADRA1ADRD3MEN1KMT2A
SCHEMBL5655919 0.83 KMT2A (0.53) DRD2ADRA1ADRD3MEN1KMT2A
SCHEMBL6416891 0.83 L3MBTL1 (0.58) DRD2ADRA1ADRD3MEN1KMT2A
SCHEMBL6417708 0.82 MAPT (0.43) DRD2ADRA1ADRD3VCPKMT2A
SCHEMBL6190931 0.82 MAPT (0.52) DRD2ADRA1ADRD3MEN1KMT2A
SCHEMBL5657975 0.81 MAPT (0.59) MEN1KMT2ANPC1SMN1; SMN2MAPT
SCHEMBL5656010 0.81 DRD2 (0.49) DRD2ADRA1ADRD3MEN1KMT2A
SCHEMBL5657782 0.81 KMT2A (0.63) MEN1KMT2ANPC1SMN1; SMN2MAPT
SCHEMBL5656137 0.81 NPC1 (0.51) MEN1KMT2ANPC1SMN1; SMN2MAPT
SCHEMBL14457597 0.81 DRD2 (0.52) DRD2MEN1KMT2ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050267126-A1 Compounds derived from aryl carbamates, preparation thereof and uses of same CEREP (FR) 2005-12-01 US claimed
US-20050267126-A1 Compounds derived from aryl carbamates, preparation thereof and uses of same CEREP (FR) 2005-12-01 US disclosed
EP-1530564-A2 COMPOUNDS DERIVED FROM ARYL CARBAMATES, PREPARATION THEREOF AND USES OF SAME Cerep (FR) 2005-05-18 EP disclosed
WO-2004018436-A2 COMPOUNDS DERIVED FROM ARYL CARBAMATES, PREPARATION THEREOF AND USES OF SAME CEREP (FR) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267126-A1 Compounds derived from aryl carbamates, preparation thereof and uses of same HTR4, HTR2B, HTR1B DRD2 96/4885ADRA1A 348/4885DRD3 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.